GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or relapsed small-cell lung cancer. Read More